Strategic partnerships Potential sales opportunities exist in leveraging Quad Technologies' collaboration model with clinical, pharmaceutical, and translational research partners. target accounts include biotech firms and contract research organizations (CROs) engaged in cell therapy workflows, CAR-T development, and stem cell therapies to licence or adopt MagCloudz technology.

Platform cross-sell Promote integration opportunities between Quad Technologies' MagCloudz cell separation kits and complementary platforms from Bio-Techne portfolio, or related imaging and analytical tools (e.g., icIEF, mass photometry) to offer an end-to-end cell processing workflow enhancement.

Early-stage traction With a small team and revenue under one million, emphasize scalable, cost-effective solutions that reduce cell viability trade-offs. Position Quad as a nimble partner for early-stage labs and startups seeking rapid deployment for translational medicine projects.

Expansion catalysts Capitalize on recent news of collaborations and technology integrations to propose joint marketing and co-development opportunities with industry thought leaders. Target labs pursuing T cell purification, CTC isolation, and regenerative medicine initiatives that require label-free, high-viability cell isolation.

Global reach potential Identify geographies and institutions investing in cell therapy pipelines and translational medicine. Given a cloud-enabled tech stack and remote collaboration potential, offer scalable procurement, training, and support packages to expand adoption across research institutions and hospitals.